Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Charles River lays off around 70 staffers in relocation as strategic shift begins
(2d)
VC Sofinnova ropes in €650M for biotech, medtech despite 'volatile' environment
(2d)
Sensei shrinks workforce by 65%, terminates 3 executive roles
(2d)
BioPharma Dive
Sofinnova Partners raises another $750M to back biotech, medtech startups
(2h)
To Wall Street, a new bidding war puts Alkermes in a tough spot
(2d)
Bristol Myers, J&J’s new blood thinner fails first big test
(2d)
Endpoints News
Sofinnova secures $750M for eleventh fund focused on drugmakers nearing the clinic
(1h)
Inside the Metsera bidding war; PD-(L)1xVEGF bispecific race heats up; Pazdur tapped as next CDER head; and more
(1d)
FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing study
(2d)
BioSpace
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant
(2d)
Bayer Layoffs Continued in Q3 but CEO Says Cuts Should Be ‘Incremental’ Moving Forward
(2d)
Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
(2d)
STAT News
I spent two hours telling a chatbot about mental health problems. Its responses scared me
(1d)
A close friend grapples with James Watson’s complicated legacy
(1d)
Medicare premiums to jump 10% heading into 2026
(2d)
BioPharma Trend
Insilico and Eli Lilly Launch $100M Collaboration for AI-Driven Drug Discovery
(6d)
Insilico Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI
(1w)
Companies Making Automated Drug Discovery a Reality
(2w)
Drug Channels
The $700 Copay That Changed Everything
(2d)
Medicare Part D 2026: Preferred Networks Vanish as the PDP Market Collapses
(3d)
Drug Channels Outlook 2026: Live Webinar with Adam J. Fein, Ph.D., on PBMs, Part D, DTC Strategies, Drug Policy Trends, and More
(4d)
European Biotechnology Magazine
Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
(2h)
Medicxi announces new €500m biotech investment fund
(18h)
Virometix: US$15m for Synthetic Vaccines
(2d)
Drug Hunter
taletrectinib
(2d)
Will a New Binding Approach Reinvigorate Caspase-1 as a Therapeutic Target for Autoimmune Disorders?
(3d)
nerandomilast (BI 1015550)
(4d)
Labiotech.EU
10 gene therapy companies you should know about
(2d)
Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology
(2d)
iGEM Jamboree: leap into the synthetic biology future
(3d)
Bio IT World
Why Are We Focused on Simulation-based Methods for Predicting Binding Affinity?
(2d)
Why Overlooking Female Biology Still Impairs Drug Development
(4d)
United Genetic, Epigenetic Readouts From The Same DNA Molecule
(5d)
GEN News
StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia
(2h)
Merck to Acquire Cidara for $9.2B, Bolstering Antiviral Pipeline
(1d)
Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine
(1d)
Cure Today
Understanding Stage 2 Vaginal Cancer: Symptoms, Diagnosis, and Treatment
(7h)
Understanding Stage 2 Myeloma with Treatment and Next Steps Explained
(11h)
An Overview of Pancreatic Neuroendocrine Tumors (PNETs)
(1d)
Contract Pharma
Contracting & Outsourcing 2025: Q&A with John Bender of Woodstock
(2d)
Merck 3Q Results
(2d)
Pfizer 3Q Results
(2d)
Pharma Times
Eisai shares long-term data on lecanemab at neurology congress
(3d)
Mursla Bio partners with global pharma to advance precision medicine in liver disease
(3d)
Evotec earns milestone payment as FDA clears IND for CELMoD candidate
(4d)
Medcity News
Why Shared Savings Still Isn’t a Viable Business Model for Hospitals
(2h)
Startup Iambic Raises $100M for Clinical Trials of AI-Discovered Cancer Drugs
(9h)
Late-in-Life Autism Diagnosis: Why Adults Still Face So Many Barriers and How We Can Do Better
(12h)
Chemical & Engineering News
Formula-linked infant botulism outbreak prompts food safety questions
(2d)
Nov. 14 Policy Watch: US government reopens, is absent from COP 30 climate conference
(2d)
Small molecule targets glucose processing to slow tumor growth
(2d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to November 14
(15h)
November EMA/CHMP batch of novel medicines backed for approval
(1d)
Switzerland seen as a safe haven for the life sciences
(1d)
Targeted Oncology
The Targeted Pulse: FDA Decisions and Clinical Advancements
(14h)
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
(1d)
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
(2d)
MedWatch
Lars Rebien is the new chairman at Novo Nordisk
(2d)
CFO rejects notion that collapsed takeover has had consequences for Bavarian Nordic
(2d)
Lundbeck to acquire Irish biotech company for up to USD 2.25bn
(2d)
In The Pipeline
Huge Channels or No Channels: You Pick
(2d)
Biochemical Tungsten - Really
(3d)
Reaction Stirring, Part Two
(4d)
Pharmaphorum
Sanofi's type 1 diabetes drug poised for EU rollout
(2d)
Lundbeck makes bid for Avadel, trying to displace Alkermes
(2d)
Kura scores FDA okay for rival to Syndax's leukaemia drug
(2d)
Drug Discovery Weekly
This week in Drug Discovery (10 – 14 November)
(2d)
New platform hopes to solve strategic misalignment in biopharma
(2d)
Positive data announced for treatment-resistant depression drug
(2d)
HIT Consultant
How Visitor Management Can Make or Break Safety Plans
(2d)
“How to Make Wound Recovery and the Healing Process More Accessible in America”
(2d)
Carrot Partners with ŌURA and Dexcom to Power Metabolic-Fertility Health with Biometric Data
(2d)
Insights: Pink Sheet
Sarepta’s Elevidys Limited To Ambulatory DMD Patients; Study In Non-Ambulatory Patients Planned
(2d)
Adverse Events: Professional Education, Electronic Records Integration Would Improve Report Quality
(2d)
CNPV II: Secondary Indications Feature In Second Batch Of US FDA Voucher Winners
(2d)
BioXconomy
Supporting the growth of clinical trials in Africa
(2d)
Africa’s clinical trial expansion hindered by logistics challenges despite growing population
(2d)
Clinical trial design and operations in genome editing therapeutics
(2d)
BioCentury
EMA’s CHMP recommends five new products
(2d)
Catalyst-driven week in venture and public equity: Finance Report
(2d)
FDA’s label changes to Sarepta’s Elevidys address physician concerns
(2d)